Olaparib

LYNPARZA®

Antineoplastic landscape

About LYNPARZA®

  1. Marketed by AstraZeneca
  2. Poly ADP ribose polymerase (PARP) inhibitor
  3. Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, metastatic breast, metastatic pancreatic or primary peritoneal cancer who have had complete or partial response to platinum-based chemotherapy

Approvals

  1. First U.S. approval date – December 16, 2014
  2. First E.U. approval date – December 19, 2014

Constraint date forecast:

  1. Orphan Drug Exclusivity expiry: 2024 (United States)
  2. SPC expiries: 2029 (European Union)
  3. Patent expiries: 2024 (Japan)

The future of the generics landscape

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team